mAbsolve
Private Company
Funding information not available
Overview
mAbsolve is a private, pre-revenue biotech platform company with a mission to improve the safety and efficacy of therapeutic antibodies by eliminating off-target Fc-mediated toxicity. Its core asset is the STR technology, a novel combination of three mutations in the Fc domain engineered to be 'truly silent,' showing no detectable binding to Fc receptors or C1q in assays, outperforming established standards like LALA and aglycosylation. The company's business model is based on non-exclusive licensing of STR to therapeutic developers, with success-based milestone payments and no royalties, targeting the approximately 50% of antibody/Fc-fusion candidates in development where effector function is undesirable.
Technology Platform
STR (Silent Fc Receptor) technology, a novel combination of three mutations in the antibody Fc domain engineered to completely eliminate binding to Fc gamma receptors and C1q, thereby ablating all Fc-mediated effector functions (ADCC, ADCP, CDC) while maintaining wild-type developability, stability, and half-life.
Opportunities
Risk Factors
Competitive Landscape
mAbsolve's primary competitors are not other companies, but the widely adopted, public-domain Fc silencing mutations like LALA/LALAPG and aglycosylation. It also competes with other proprietary Fc engineering platforms from companies like Bolt Biotherapeutics (for immune stimulation, but which may offer silencing options) and various biotech tools firms. Its key differentiator is the claim of 'true silence' with no detectable residual binding, backed by published data.